Navigation Links
Study Shows Lantus(R) Helped People Living with Type 2 Diabetes Reach the ADA's Recommended Target for Blood Sugar Control

New data presented at the ADA's Annual Scientific Sessions demonstrated the value of beginning insulin promptly when glycemic targets are not achieved

with diet, exercise and oral medications alone

SAN FRANCISCO, June 7 /PRNewswire-FirstCall/ -- Results from a new study presented at the American Diabetes Association's (ADA) 68th Annual Scientific Sessions reinforce the importance of promptly initiating insulin treatment when patients with type 2 diabetes are unable to achieve recommended glycemic targets with diet, exercise and oral diabetes medications alone. In the TULIP (Testing the Usefulness of Lantus(R) when Initiated Promptly in patients with type 2 diabetes) clinical study, 66 percent of patients who began treatment with the long-acting, basal insulin Lantus(R) (insulin glargine [rDNA origin] injection) achieved A1C <7%, the ADA's recommended target for glycemic control, while only 38 percent of patients from the lifestyle management arm were able to achieve the recommended target levels.

In an effort to help guide treatment decisions, the ADA and European Association for the Study of Diabetes (EASD) developed a Consensus Algorithm for Type 2 Diabetes that calls for healthcare providers and diabetes patients to initiate insulin therapy when A1C <7% is not achieved with oral medications and lifestyle management alone. However, physicians typically wait for A1C to approach 9% before adding insulin. In general, every percentage point drop in A1C blood test results (e.g., from 8.0% to 7.0%) reduces the risk of microvascular complications (eye, kidney, and nerve diseases) by 40%.

The most common side effect of any insulin, including Lantus(R), is hypoglycemia, which may be serious. In the Lantus(R) arm of the TULIP trial, there were 4.2 +/- 6.6 (p<0.0001) cases of symptomatic, 0.7 +/- 2.1 (p=0.0011) cases of nocturnal and 0.04 +/- 0.35 (p=0.147) cases of severe hypoglycemia events reported per patient year. However, no patients dropped out of the trial due to hypoglycaemia.

"When glycemic targets are not achieved with diet, exercise and oral medications given at maximum tolerated dose, patients with type 2 diabetes have reached a critical moment in the lifecycle of their condition," said Andre Grimaldi, MD, Professor Diabetes Department Head, Pitie-Salpetriere Hospital, Paris, France. "The results observed in TULIP demonstrate the value of following the ADA/EASD treatment recommendations by initiating basal insulin therapy in a timely manner."

About the TULIP Study

TULIP is a 9-month, 12-visit, open-label, multinational, multicenter, randomized study to evaluate starting Lantus(R) or intensifying lifestyle management in type 2 diabetes patients aged 40-75 years, body mass index (BMI) 24-35 kg/m2 and A1C 7-8%, treated with maximum doses of metformin and sulfonylurea for greater than or equal to 2 years. Lantus(R) was injected once-daily and titrated to capillary fasting blood glucose 70-100 mg/dL. In the lifestyle management arm, dietary and physical activity counseling recommended stable weight for people with BMI<27 kg/m2 or weight loss of 3 kg for patients with BMI greater than or equal to 27 kg/m2. 215 patients were randomized to Lantus(R) (n=106) or lifestyle management (n=109).

The primary objective was the percentage of patients achieving A1C <7% at endpoint. Secondary endpoints included changes in A1C and fasting plasma glucose (FPG), and hypoglycemia incidence.

211 (52.6% male) patients were randomized and treated; mean ( +/-standard deviation) age 60.7 +/- 7.9 years, weight 84.5 +/- 13.1 kg, BMI 29.9 +/- 3.5 kg/m2 and A1C 7.6 +/- 0.4%. More patients reached A1c <7% (66 vs 38%; p<0.0001) or <6.5% (34 vs 11%; p<0.0001) with Lantus(R) versus lifestyle management. In contrast to the Lantus(R)-treated group, the lifestyle management-treated group showed a decrease in weight (+0.9 +/- 2.9 vs -2.5 +/- 3.2 kg; p<0.0001) as well as the expected lower hypoglycemia.
Results for hypoglycemia, A1C, FPG and weight are shown in the table.

A1C, FPG, body weight, insulin dose and hypoglycemia

Lantus(R) LM p

(n=103) (n=108)

% of <7% at

patients endpoint; 66; 38;

with A1C at <6.5% at <0.0001;

endpoint endpoint 34 11 <0.0001

Baseline; 7.6 +/- 0.3; 7.5 +/- 0.4;

A1C (%) Endpoint; 6.8 +/- 0.7; 7.3 +/- 0.9; <0.0001*

Change -0.8 +/- 0.7 -0.2 +/- 0.9

Baseline; 170 +/- 34; 167 +/- 27;

FPG (mg/dL) Endpoint; 122 +/- 33; 161 +/- 41; <0.0001*

Change -50 +/- 47 -5 +/- 39

Baseline; 85.0 +/- 12.5; 84.0 +/- 13.7;

Weight (kg) Endpoint; 86.0 +/- 13.4; 81.5 +/- 13.5; <0.0001*

Change +0.91 +/- 2.9 -2.5 +/- 3.2

Daily Starting

Lantus(R) insulin

dose (U/kg) dose; 0.12 +/- 0.05; n/a;

Endpoint 0.27 +/- 0.15 n/a n/a


(events Symptomatic; 4.2 +/- 6.6; 2.0 +/- 7.8; <0.0001;

patient per Nocturnal; 0.7 +/- 2.1; 0.3 +/- 2.1; 0.0011;

year) Severe 0.04 +/- 0.35 0.00 +/- 0.00 0.147

Results are given for all randomized and treated patients; 4 patients (Lantus(R), 3; LM, 1) were randomized but not treated. Results are means +/- standard deviation; *p value for between-group difference in baseline to endpoint change; FPG=fasting plasma glucose; LM=lifestyle management; n/a=not applicable

About Diabetes

Diabetes is a chronic, widespread condition in which the body does not produce or properly use insulin -- the hormone needed to transport glucose (sugar) from the blood into the cells of the body for energy. More than 230 million people worldwide are living with the disease. This number is expected to rise to a staggering 350 million within 20 years. It is estimated more than 20 million Americans have diabetes, including an estimated 6.2 million who remain undiagnosed.

At the same time, approximately 43% of those diagnosed are not achieving the blood sugar control target of A1C <7% recommended by the American Diabetes Association (ADA).

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

U.S. Media Contact:

Carrie Melia



Media Relations: Tel. 908-981-6567


Investor Relations: Tel. 908-981-5560



SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications
2. Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer
3. Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients
4. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
5. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
6. Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
7. Wound Management Technologies, Inc. Announces Evidence Based Study
8. CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCytes Glycoprotein Products in Heart Attack Disease Model
9. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
10. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
11. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
Post Your Comments:
(Date:9/22/2017)... Md. , Sept. 22, 2017  As the ... Republican Senators Bill Cassidy (R-LA) and ... Information notes that the medical device industry is in ... medical device tax, the 2.3% excise tax on medical ... But they also want covered patients, increased visits and ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017  PMD ... OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... strategic hub service that expedites and streamlines patient and ... Spiro PD 2.0, and wellness management services.  ... medical device used to measure lung function for a ...
(Date:9/12/2017)... 12, 2017  Consumer reviews on the independent review site ... number one company for hearing aids, ranking it higher than ... ... by Consumers For Hearing Aids ... is an online store that provides high performance, state-of-the-art, German-engineered hearing ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... ... serving communities in the greater Dallas, Miami, and Raleigh regions, is organizing an ... to overcome a rare and deadly chromosome abnormality. , After struggling since birth ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... the certification process to promote standards of excellence for the field of eating ... for March 22 – 25, 2018 in Orlando, Florida at the Omni Resort ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, ... lowdown on sciatica in a new episode of "Success Files," which is an ... and innovation and investigates each subject in-depth with passion and integrity. , Sciatica ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
Breaking Medicine News(10 mins):